Sodium algorithm for Premature Births

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Children's wisconsin, Milwaukee, WI
Premature Births+1 More
Sodium algorithm - Procedure
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this project is to determine the direct impact of sodium supplementation in preterm infants and to see the overall improvement of their growth and health status. from this study will help us develop a better treatment for in the future.

Eligible Conditions

  • Premature Births

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 8 weeks

8 weeks
Microbiome
Preterm infant weight gain

Trial Safety

Trial Design

2 Treatment Groups

Control
1 of 2
Sodium algorithm
1 of 2
Active Control
Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: Sodium algorithm · No Placebo Group · Phase < 1

Sodium algorithm
Procedure
Experimental Group · 1 Intervention: Sodium algorithm · Intervention Types: Procedure
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks
Closest Location: Children's wisconsin · Milwaukee, WI
Photo of Milwaukee 1Photo of Milwaukee 2Photo of Milwaukee 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Premature Births
0 CompletedClinical Trials

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
545 Previous Clinical Trials
1,150,355 Total Patients Enrolled
Jeffrey Segar, MDPrincipal InvestigatorMedical College of Wisconsin
1 Previous Clinical Trials
1 Total Patients Enrolled

Eligibility Criteria

Age < 18 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are less than 14 days old at the time of randomization.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.